Publications (20) JOSÉ PABLO MIRAMONTES GONZÁLEZ publications

filter_list

2019

  1. A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function

    Scientific Reports, Vol. 9, Núm. 1

  2. Could renin-angiotensin-aldosterone system activation explain the amputations associated with canagliflozin? The nitric oxide hypothesis

    Diabetes Research and Clinical Practice, Vol. 148, pp. 10-13

  3. Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors

    Revista Clinica Espanola, Vol. 219, Núm. 4, pp. 208-217

  4. Erratum: Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease (American Journal of Physiology - Renal Physiology (2018) 315 (F1406-F1415) DOI: 10.1152/ajprenal.00384.2017)

    American Journal of Physiology - Renal Physiology

  5. GLP-1 and the renin–angiotensin–aldosterone system

    The Lancet Diabetes and Endocrinology

  6. In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways"

    Journal of Cellular Physiology

  7. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

  8. Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months

    Diabetes Research and Clinical Practice, Vol. 158

  9. VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia

    Atherosclerosis, Vol. 285, pp. 17-22

2018

  1. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease

    American Journal of Physiology - Renal Physiology, Vol. 315, Núm. 5, pp. F1406-F1415

  2. Diabetes tipo 2 bien contralada y microalbuinuria

    Revista Española de Casos Clínicos en Medicina Interna (RECCMI), Vol. 3, Núm. 0, pp. 24-26

  3. Reply to 'Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes' by Yoshimoto et al

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research

  4. Reply to ‘Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes’ by Yoshimoto et al.

    Journal of Investigative Medicine

  5. The mechanism of action of sodium–glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors

    European Journal of Heart Failure

  6. Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?

    Medicina Clinica, Vol. 150, Núm. 1, pp. 33-38

  7. Use of degludec insulin in chronic complex patients

    European Journal of Internal Medicine

2017

  1. I can not wear my sunglasses: An unusual sarcoidosis presentation

    Korean Journal of Family Medicine, Vol. 38, Núm. 4, pp. 226-228

  2. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

    Circulation, Vol. 135, Núm. 22, pp. 2133-2144

2016

  1. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

    Journal of the American College of Cardiology, Vol. 67, Núm. 11, pp. 1278-1285

2015

  1. Molecular mechanism for hypertensive renal disease: Differential regulation of chromogranin a expression at 3′-untranslated region polymorphism C+87T by MicroRNA-107

    Journal of the American Society of Nephrology, Vol. 26, Núm. 8, pp. 1816-1825